Rani Therapeutics, a Silicon Valley company backed by Alphabet, has completed its first human study of its RaniPill, a pill capable of delivering biologic drugs such as insulin and AbbVie’s Humira into the wall of the small intestine. Alphabet is investing in other areas of biotechnology as well, indicated by Google's recently filed patent application for a system that uses AI to remotely monitor patients or babies sleeping.